Development of hepatocellular carcinoma in Japanese patients with biopsy-proven non-alcoholic fatty liver disease: Association between PNPLA3 genotype and hepatocarcinogenesis/fibrosis progression

Hepatology Research

Volumn 47, Issue 11, 2017, Pages 1083-1092

  Seko, Yuya ^a   Sumida, Yoshio ^a   Tanaka, Saiyu ^b   Mori, Kojiroh ^b   Taketani, Hiroyoshi ^a   Ishiba, Hiroshi ^a   Hara, Tasuku ^a   Okajima, Akira ^a   Umemura, Atsushi ^a   Nishikawa, Taichiro ^a   Yamaguchi, Kanji ^a   Moriguchi, Michihisa ^a   Kanemasa, Kazuyuki ^b   Yasui, Kohichiroh ^a   Imai, Shunsuke ^b   Shimada, Keiji ^b   Itoh, Yoshito ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b Nara City Hospital   (Japan)

Author keywords

hepatocellular carcinoma; NAFLD; PNPLA3

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; COHORT ANALYSIS; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; FOLLOW UP; GENE; HUMAN; HUMAN CELL; INCIDENCE; JAPANESE (PEOPLE); LIVER BIOPSY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PNPLA3 GENE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTE COUNT;

EID: 85007162511     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12840     Document Type: Article

References (47)

1. Health and Welfare Statistics Association. 2013 Japan. Journal of Health and Welfare Statistics 2013; 60: 51–75.
2. Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005–2023.
3. Watanabe S, Hashimoto E, Ikejima K et al. Japanese Society of Gastroenterology; Japan Society of Hepatology. Evidence based clinical practice guidelines for nonalcoholic fatty liver disease/ nonalcoholic steatohepatitis. J Gastroenterol 2015; 50: 364–377.
4. Hui JM, Kench JG, George J et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003; 38: 420–427.
5. Sugimoto K, Takei Y. Clinicopathological features of non-alcoholic fatty liver disease. Hepatol Res 2011; 41: 911–920.
6. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820–1832.
7. Seko Y, Sumida Y, Tanaka S et al. Predictors of malignancies and overall mortality in Japanese patients with biopsy-proven non-alcoholic fatty liver disease. Hepatol Res 2015; 45: 728–738.
8. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: S5–S6.
9. Falleti E, Fabris C, Pirisi M et al. Interleukin-6 polymorphisms and gender: relationship with the occurrence of hepatocellular carcinoma in patients with end-stage liver disease. Oncology 2009; 77: 304–313.
10. Yang Y, Luo C, Feng R, Bi S. The TNF-α, IL-1B and IL-10 polymorphisms and risk for hepatocellular carcinoma: a metaanalysis. J Cancer Res Clin Oncol 2011; 137: 947–952.
11. Hernaez R. Genetic factors associated with the presence and progression of nonalcoholic fatty liver disease: a narrative review. Gastroenterol Hepatol 2012; 35: 32–41.
12. Chalasani N, Guo X, Loomba R et al. Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease. Gastroenterology 2010; 139: 1567–1576.
13. Speliotes EK, Yerges-Armstrong LM, Wu J et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011; 7: e1001324.
14. Kawaguchi T, Sumida Y, Umemura A et al. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS One 2012; 7: e38322.
15. Yuan X, Waterworth D, Perry JRB et al. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet 2008; 83: 520–528.
16. Hotta K, Yoneda M, Hyogo H et al. Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease. BMC Med Genet 2010; 11: 172.
17. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011; 53: 1883–1894.
18. Guyot E, Sutton A, Rufat P et al. PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction inpatients with cirrhosis. J Hepatol 2013; 58: 312–318.
19. Nischalke HD, Berger C, Luda C et al. The PNPLA3 rs738409 148 M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis. PLoS One 2011; 6: e27087.
20. Trepo E, Guyot E, Ganne-Carrie N et al. PNPLA3 (rs738409 C > G) is a common risk variant associated with hepatocellular carcinoma in alcoholic cirrhosis. Hepatology 2012; 55: 1307–1308.
21. Trepo E, Nahon P, Bontempi G et al. Association between the PNPLA3 (rs738409 C > G) variant and hepatocellular carcinoma: evidence from a meta-analysis of individual participant data. Hepatology 2014; 59: 2170–2177.
22. Valenti L, Rumi M, Galmozzi E et al. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 2011; 53: 791–799.
23. Falleti E, Fabris C, Cmet S et al. PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence. Liver Int 2011; 31: 1137–1143.
24. Liu YL, Patman GL, Leathart JB et al. Carriage of the PNPLA3 rs738409 C < G polymorphism confers an increased risk of nonalcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol 2014; 61: 75–81.
25. Ueyama M, Nishida N, Korenaga M et al. The impact of PNPLA3 and JAZF1 on hepatocellular carcinoma in non-viral hepatitis patients with type 2 diabetes mellitus. J Gastroenterol 2016; 51: 370–379
26. Takeuchi Y, Ikeda F, Moritou Y et al. The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis. J Gastroenterol 2013; 48: 405–412.
27. Younossi ZM, Stepanova M, Rafiq N et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011; 53: 1874–1882.
28. Matteoni CA, Younossi ZM, Gramlich T et al. Nonalcoholic fatty liver diseases: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413–1419.
29. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313–1321.
30. Brunt EM, Janney CG, Di Bisceglie AM et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467–2474.
31. Hashimoto E, Yatsuji S, Tobari M et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol 2009; 44(Suppl 19): 89–95.
32. Kawamura Y, Arase Y, Ikeda K et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol 2012; 107: 253–261.
33. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012; 10: 1342–1359.
34. Valenti L, Al-Serri A, Daly AK et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51: 1209–1217.
35. Sookoian S, Castano GO, Burgueno AL, Gianotti TF, Rosselli MS, Pirola CJ. A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res 2009; 50: 2111–2116.
36. Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010; 52: 894–903.
37. Al-Serri A, Anstee QM, Valenti L et al. The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case–control and intra-familial allele association studies. J Hepatol 2012; 56: 448–454.
38. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012; 56: 1384–1391.
39. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 2013; 10: 656–665.
40. Lade A, Noon L, Friedman SL. Contributions of metabolic dysregulation and inflammation to non-alcoholic steatohepatitis, hepatic fibrosis, and cancer current reviews. Oncology 2014; 26: 100–107.
41. Yoneda M, Fujii H, Sumida Y et al. Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. J Gastroenterol 2011; 46: 1300–1306.
42. Seko Y, Sumida Y, Tanaka S et al. Serum alanine aminotransferase predicts the histological course of non-alcoholic steatohepatitis in Japanese patients. Hepatol Res 2015; 45: E53–E61.
43. Romeo S, Kozlitina J, Xing C et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461–1465.
44. Palmer ND, Musani SK, Yerges-Armstrong LM et al. Characterization of European ancestry nonalcoholic fatty liver disease-associated variants in individuals of African and Hispanic descent. Hepatology 2013; 58: 966–975.
45. Hernaez R, McLean J, Lazo M et al. Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third National Health and Nutrition Examination Survey. Clin Gastroenterol Hepatol 2013; 11: 1183–1190.
46. Zhang Y, Cai W, Song J et al. Association between the PNPLA3 I148M polymorphism and non-alcoholic fatty liver disease in the Uygur and Han ethnic groups of northwestern China. PLoS One 2014; 9: e108381.
47. Lee SS, Byoun YS, Jeong SH et al. Role of the PNPLA3 I148M polymorphism in nonalcoholic fatty liver disease and fibrosis in Korea. Dig Dis Sci 2014; 59: 2967–2974.